Immunity (Cell Press) 'Under Review': What Each Status Means

Immunity uniquely supports presubmission inquiries. Authors uncertain about scope can submit an abstract to Immunity and receive feedback within 2 to 5 business days about whether the work is suitable for the journal. This is particularly valuable for translational immunology work where the boundary between Immunity, Cell Reports Medicine, and JCI is unclear. A "yes" response to a presubmission inquiry significantly shortens the desk-screen risk during full submission.

Before the paper reaches external reviewers, a Cell Press consulting editor at Immunity evaluates whether the immunology mechanism warrants Immunity's selective editorial slots. About 75 to 80 percent of submissions are returned at this stage within 3 to 5 business days. A desk rejection most often means the consulting editor concluded that the work would fit better at a sister Cell Press title (Cell Reports, Cell Reports Medicine, iScience) or that the broad-immunology audience fit is uncertain.

The Cell Press editorial office confirms files are complete: manuscript with figures embedded, supplementary information separate, reporting checklists where applicable (ARRIVE for animal work, MIQE for quantitative PCR, CONSORT for any clinical-trial component, STROBE for observational immunology studies), STAR Methods compliance documentation, cover letter directed to the editor, conflict-of-interest declarations, and ethics-statement documentation including IACUC and IRB approvals.

The consulting editor reads the paper and evaluates immunology mechanism depth, broad-immunology audience fit, and whether orthogonal-method validation supports the central claim.

In parallel with the consulting editor's primary read, ambiguous-fit papers are discussed at the Cell Press editor meeting where peer consulting editors at sister Cell Press titles weigh in on whether the paper would fit better at Immunity, Cell Reports, or Cell Reports Medicine. This editorial-team discussion runs alongside the desk-screen and adds 1 to 3 days to the front-end timeline.

Cell Press consulting editors at Immunity typically invite two to three external reviewers. The recruitment window can take 7 to 14 days because immunology reviewers with topic-matched expertise (e.g., innate-immunity mechanism + clinical translation, T-cell biology + structural immunology) are scarce. Reviewer invitations from Cell Press are weighted higher than most Elsevier titles.

Once reviewers agree to review, the typical Immunity peer-review cycle lasts 14 to 21 days, contributing to Cell Press's 3 to 4 week first-decision target. Reviewers are asked to evaluate mechanism depth, orthogonal-method validation, broad-immunology framing, and reproducibility. Reviewer reports for Immunity tend to be thorough; 2000 to 4000 word reports are typical.

After both reports return, the consulting editor synthesizes them. The 3 to 4 week first-decision target applies to papers that reach external peer review. Manuscripts invited for revisions have a 2 to 3 month revision timeline; accepted papers are published within 10 weeks of acceptance per Cell Press editorial guidance.

• Rejection within 1 to 3 days: Administrative issue or immediate scope mismatch.

• Rejection within 3 to 5 business days: Consulting editor desk rejection. Most rejections happen here.

• Still Under Review after 2 weeks: Strong signal. Paper passed the steepest Cell Press filter.

• Still Under Review after 8 weeks: Reviewer-recruitment or reviewer-report delay. A polite inquiry to immunity@cell.com is appropriate.

• Status changes to "Decision Pending": Reports are in; expect a decision within 1 to 2 weeks.

This is the most common anxiety we hear from Immunity authors during the active editorial window. The honest answer: no, 4 weeks puts you right at the edge of Cell Press's 3 to 4 week first-decision target. Reports may already be in editorial synthesis with the consulting editor preparing a recommendation. The 4-week mark is typically NOT a worry signal at Immunity. Most reviewer-driven delays come from reviewer-recruitment timing rather than slow reviews.

If the portal still says Under Review at the 6-week mark, the most likely explanation is reviewer extension granted by the consulting editor. This is normal practice at Cell Press.

What you should NOT do during the 4-to-6-week window is email the editorial office. Cell Press consulting editors at Immunity are managing 40+ active papers; an inquiry at 4 weeks adds friction without accelerating the timeline.

If your Immunity paper is rejected after review, the natural cascade depends on what the reviewers and consulting editor cited:

Cell Reports is the most natural Cell Press cascade because Cell Press editors transfer manuscripts directly via the portable peer-review system, preserving reviewer reports for the receiving editor. Cell Reports has a broader scope; papers rejected from Immunity for broad-audience reasons often fit Cell Reports cleanly. The transfer process takes 5 to 10 days because Cell Press carries the reviewer reports across.

Cell Reports Medicine is a secondary cascade option for translational immunology papers where the clinical-translation framing is stronger than the basic-immunology mechanism. Cell Reports Medicine accepts both basic and translational work but weights clinical relevance more heavily.

Nature Immunology is a cascade option for papers where the broader immunology framing is stronger than the mechanism specificity, particularly for systems-immunology or cell-fate papers. Nature Immunology operates separately from Cell Press but accepts manuscripts at a comparable bar.

Cell Press asks reviewers at Immunity to evaluate four things specifically. The table below maps each to actionable preparation.

Across Immunity manuscripts, and across Manusights review data from 50+ immunology and Cell Press-targeted manuscripts, three patterns generate the most consistent reviewer concerns we see at Immunity. These patterns matter because an Under Review status often means the consulting editor saw a plausible top-immunology story, but reviewers are now testing whether the manuscript components prove mechanism, scope, and reproducibility.

Single-method mechanism without orthogonal confirmation. When the central immunology mechanism rests on one experimental approach, such as only conditional knockout, only antibody depletion, only inhibitor treatment, or only an omics association, Immunity reviewers consistently request a second orthogonal validation. The strongest manuscripts pair perturbation with rescue, in-vivo phenotyping, cellular readouts, or independent molecular assays before submission.

Narrow immunology framing flagged for broad-audience fit. When the introduction frames the work too narrowly around one cell type, one pathogen, one tissue, or one disease context, broad-immunology framing concerns surface from at least one Immunity reviewer. The strongest manuscripts make the broader immunology principle visible in the title, abstract, first figure, and final introduction paragraph, not only in the discussion.

Cell Press venue mismatch flagged by consulting editor. When the consulting editor concludes the work is sound but the broad-immunology audience appeal is uncertain, transfer offers to Cell Reports or Cell Reports Medicine are common. Authors should consider a presubmission inquiry to clarify fit before full submission and should keep reviewer-response language portable enough to reuse inside the Cell Press transfer system.

We also check whether the figure legends, Key Resources Table, and cover letter reinforce the same mechanism claim, because Immunity reviewers often notice when the narrative is stronger than the validation package.

Source limitation: this guidance combines official guidance, public status and timing signals, and anonymized Manusights pre-submission review patterns; it does not use private Cell Press editorial records. Compared with official guidance, the useful reader-facing value is translating the status into mechanism, orthogonal-validation, STAR Methods, cover-letter, and Cell Press routing checks authors can act on while waiting.

This page was created from Cell Press's public author guidance at Cell Press author instructions, Cell Press Editorial Manager documentation, Cell Press editorial-speed guidance, and Manusights pre-submission review experience with Immunity-targeted manuscripts. Numeric claims about desk-decision and review-time windows are sourced to Cell Press editorial-speed metrics.

For the Cell Press immunology landscape beyond Immunity, start with the Immunity journal overview, the Immunity submission guide, the Immunity review-time guide, and the Immunity cover-letter guide.

Then compare Cell Reports (broader scope, faster turnaround, Cell Press portable peer-review transfer), Cell Reports Medicine (clinical-translation focus), Cell Host & Microbe, and iScience (open-access alternative across Cell Press). The choice across these titles depends on whether the central contribution is mechanism-depth-with-broad-audience (Immunity), broader biology (Cell Reports), host-microbe immunology (Cell Host & Microbe), translational-clinical (Cell Reports Medicine), or open-access (iScience).

For technical issues during Cell Press submission, the editorial office at immunity@cell.com handles most queries via the manuscript record.

Reviewers at Immunity typically draw from one mechanism-focused immunology expert and one broader-cell-biology or clinical-translation specialist. Preparing a response template that addresses both perspectives accelerates revision rounds substantially.

For a pre-upload check of your manuscript against the Immunity mechanism-depth-plus-broad-audience bar before submission, our Immunity pre-submission diagnostic flags the orthogonal-validation gaps and narrow-framing weaknesses most likely to surface in reviewer reports.